Technical Analysis for VRTX - Vertex Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
grade D 147.04 1.33% 1.93
VRTX closed up 1.33 percent on Wednesday, November 22, 2017, on 60 percent of normal volume.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Flat
See historical VRTX trend table...

Date Alert Name Type % Chg
Nov 20 MACD Bearish Signal Line Cross Bearish 1.66%
Nov 17 NR7 Range Contraction -0.25%
Nov 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.61%
Nov 15 50 DMA Resistance Bearish -1.09%
Nov 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.09%
Nov 14 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.53%
Nov 13 NR7 Range Contraction -0.72%
Nov 8 Bearish Engulfing Bearish -0.24%
Nov 8 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.24%
Nov 8 180 Bearish Setup Bearish Swing Setup -0.24%

Older signals for VRTX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Its products include telaprevir for the treatment of adults with genotype 1 hepatitis C virus (HCV) infection, which is marketed in the United States and Canada under the INCIVEK brand name; and ivacaftor for the treatment of cystic fibrosis that is marketed in the United States, Canada, and Europe under the KALYDECO brand name. The company, through its collaboration agreement with Janssen Pharmaceutica, N.V., also markets telaprevir in Europe and other countries in Janssen's territories under the INCIVO brand name, as well as in Japan under TELAVIC brand name. It is also developing drug candidates for the treatment of cystic fibrosis, including VX-809, which is in Phase III clinical trial and VX-661 that is in Phase II clinical trial; and drug candidates for the treatment of HCV infection, such as VX-135 (ALS-2200), which is in Phase II clinical trial and VX-222 that is in Phase II clinical trial. In addition, the company develops VX-509, which is in Phase II clinical trial for the treatment of autoimmune disease; and VX-787 that is in Phase II clinical trial for the treatment of influenza. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Is VRTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 167.85
52 Week Low 71.46
Average Volume 1,506,585
200-Day Moving Average 130.3377
50-Day Moving Average 150.4808
20-Day Moving Average 147.414
10-Day Moving Average 147.363
Average True Range 3.8891
ADX 20.14
+DI 15.39
-DI 23.39
Chandelier Exit (Long, 3 ATRs ) 141.2027
Chandelier Exit (Short, 3 ATRs ) 150.7173
Upper Bollinger Band 151.8382
Lower Bollinger Band 142.9898
Percent B (%b) 0.46
BandWidth 6.002415
MACD Line -1.2404
MACD Signal Line -1.1854
MACD Histogram -0.055
Fundamentals Value
Market Cap 37.08 Billion
Num Shares 252 Million
EPS 1.04
Price-to-Earnings (P/E) Ratio 141.38
Price-to-Sales 17.01
Price-to-Book 21.57
PEG Ratio 1.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 150.91
Resistance 3 (R3) 150.60 148.99 150.27
Resistance 2 (R2) 148.99 148.01 149.15 150.05
Resistance 1 (R1) 148.02 147.40 148.51 148.33 149.83
Pivot Point 146.41 146.41 146.66 146.57 146.41
Support 1 (S1) 145.44 145.43 145.93 145.75 144.25
Support 2 (S2) 143.83 144.82 143.99 144.03
Support 3 (S3) 142.86 143.83 143.82
Support 4 (S4) 143.17